Search for other papers by Megumi Fujikawa in
Google Scholar
PubMed
Search for other papers by Ken Okamura in
Google Scholar
PubMed
Objective: As thionamide is associated with various adverse effects, we reevaluated the practical efficacy of potassium iodide (KI) therapy for Graves’ hyperthyroidism (GD).
Methods: We administered KI (mainly 100 mg/day) to 324 untreated GD patients, and added methimazole (MMI) only to those remaining thyrotoxic even at 200 mg/day. When the patient became hypothyroid, MMI if taken was stopped, then levothyroxine (LT4) was added without reducing the KI dose. Radioactive iodine (RI) therapy or thyroidectomy was performed whenever required. We evaluated the early effects of KI at 2-4 weeks, and followed patients for 2 years.
Results: At 2 weeks, serum thyroid hormone decreased in all 324 patients. At 4 weeks, fT4, fT3, and both fT4 and fT3 levels became normal or low in 74.7%, 50.6%, and 50.6%, respectively. In a cross-sectional survey over 2-years, GD was well-controlled with KI or KI+LT4 (KI-effective) in >50% of patients at all time points. Among 288 patients followed for 2 years, 42.7% remained ‘KI-effective’ throughout 2 years (KI Group), 30.9% were well-controlled with additional MMI given for 1-24 months, and 26.4% were successfully treated with ablative therapy (mainly RI). Among ‘KI-effective’ patients at 4 weeks, 76.5% were classified into KI Group. No patients experienced adverse effects of KI.
Conclusion: KI therapy was useful in the treatment of GD. A sufficient dose of KI was effective in >50% of GD patients from 4 weeks to 2 years, and 42.7% (76.5% of ‘KI effective’ patients at 4 weeks) remained ‘KI-effective’ throughout 2 years.
Search for other papers by Inge Bülow Pedersen in
Google Scholar
PubMed
Search for other papers by Peter Laurberg in
Google Scholar
PubMed
Introduction Neonatal hyperthyroidism is a rare disease. Most cases are due to placental transferal of thyroid-stimulating hormone (TSH) receptor autoantibodies (TRAb) from mothers with Graves' disease to their fetuses. Even rarer causes are
Search for other papers by Christiaan F. Mooij in
Google Scholar
PubMed
Search for other papers by Nitash Zwaveling-Soonawala in
Google Scholar
PubMed
Search for other papers by Eric Fliers in
Google Scholar
PubMed
Search for other papers by A.S. Paul van Trotsenburg in
Google Scholar
PubMed
Dear Editor, Hyperthyroidism due to Graves’ disease is primarily treated with antithyroid drugs. Thyroidectomy is mostly considered to provide definitive therapy in case of recurrent or persistent hyperthyroidism. However, carrying out this
Search for other papers by Wilmar M. Wiersinga in
Google Scholar
PubMed
The ETA guidelines on subclinical hyperthyroidism (SHyper) in the present issue of European Thyroid Journal [ 1 ], together with the previously published ETA guidelines on subclinical hypothyroidism (SHypo) [ 2 , 3 ], offer up
Search for other papers by Mahdi Kamoun in
Google Scholar
PubMed
Search for other papers by Michèle d'Herbomez in
Google Scholar
PubMed
Search for other papers by Christine Lemaire in
Google Scholar
PubMed
Search for other papers by Armelle Fayard in
Google Scholar
PubMed
Search for other papers by Rachel Desailloud in
Google Scholar
PubMed
Search for other papers by Damien Huglo in
Google Scholar
PubMed
Search for other papers by Jean-Louis Wemeau in
Google Scholar
PubMed
is rarely reported. Very few cases of coexistence of TSHoma with hyperthyroidism due to Graves' disease have been reported [ 4 , 5 , 6 , 7 , 8 , 9 ]. Here, we describe a female patient displaying TSHoma with Graves' disease who presented initially
Search for other papers by Stasa Ivkovic in
Google Scholar
PubMed
Dear Sir, Five months after radioactive iodine treatment for Graves’ hyperthyroidism, I developed severe hypothyroidism. Three months after treatment, TSH, FT4 and FT3 values were within reference range (0.44 mlU/l, 15.9 and 4.5 pmol
Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Göteborg, Sweden
The National Task Force in Hyperthyroidism, Swedish National System for Knowledge-Driven Management, Umeå, Sweden
Search for other papers by Agneta Lindo in
Google Scholar
PubMed
Department of Endocrinology and Diabetes, Örebro University Hospital, Örebro, Sweden
Search for other papers by Anne Breikert in
Google Scholar
PubMed
Thyroid Federation International, Kungsbacka, Sweden
Search for other papers by Peter Lakwijk in
Google Scholar
PubMed
Swedish Thyroid Association, Stockholm, Sweden
Search for other papers by Christin Lundberg in
Google Scholar
PubMed
Swedish Thyroid Association, Stockholm, Sweden
Search for other papers by Katarina Lunner in
Google Scholar
PubMed
Search for other papers by Birgitta Johansson in
Google Scholar
PubMed
Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Göteborg, Sweden
The National Task Force in Hyperthyroidism, Swedish National System for Knowledge-Driven Management, Umeå, Sweden
Sweden and Wallenberg Center for Molecular and Translational Medicine, Västra Götaland Region, Göteborg, Sweden
Search for other papers by Helena Filipsson Nyström in
Google Scholar
PubMed
to end up with a better disease experience and QoL. Importance of addressing patient fears and pre-morbid psychological conditions When interviewing patients with GD, ambiguous signs of the disease appear problematic ( 17 ). Hyperthyroid
Search for other papers by Alessandro Brancatella in
Google Scholar
PubMed
Search for other papers by Nicola Viola in
Google Scholar
PubMed
Search for other papers by Sandra Brogioni in
Google Scholar
PubMed
Search for other papers by Lucia Montanelli in
Google Scholar
PubMed
Search for other papers by Chiara Sardella in
Google Scholar
PubMed
Search for other papers by Paolo Vitti in
Google Scholar
PubMed
Search for other papers by Claudio Marcocci in
Google Scholar
PubMed
Search for other papers by Isabella Lupi in
Google Scholar
PubMed
Search for other papers by Francesco Latrofa in
Google Scholar
PubMed
hyperthyroidism. Case Presentation A 51-year-old male was referred to us because he had experienced palpitations, heat intolerance, and insomnia after the fourth infusion of nivolumab (3 mg/kg every 14 days) for a metastatic non-small cell lung cancer
Search for other papers by John H. Lazarus in
Google Scholar
PubMed
Introduction Maternal hyperthyroidism is reported to occur at a frequency of around 0.2% [ 1 ]. This is to be contrasted with the prevalence of antithyroid peroxidase antibodies which occur in 10% of women when measured at around 12 weeks of
Search for other papers by Matthew J. Brooks in
Google Scholar
PubMed
Search for other papers by David A. Pattison in
Google Scholar
PubMed
Search for other papers by Eliza P. Teo in
Google Scholar
PubMed
Search for other papers by Sarah Price in
Google Scholar
PubMed
Search for other papers by Ronen Gurvitch in
Google Scholar
PubMed
What Is Known about This Topic • Hyperthyroidism is a recognised cause of coronary artery spasm and routine thyroid function testing should be performed in all patients. • Thyroid dysfunction secondary to amiodarone therapy is common
